Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Multiply Recurrent Epithelial Ovarian Cancer
NCT02736305Phase 2Completed
- Sponsor
- National Cancer Centre Singapore
- Start
- Feb 2016
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by National Cancer Centre Singapore. Primary endpoint: Progression-Free Survival. Started Feb 2016; status: completed.
02
Drugs
regorafenib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02736305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736305.